← Eichor
Study identifier: NCT06665945 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

Condition: Ovarian Cancer  ·  Sponsor: University of Utah

PhaseN/A
Planned participants245
Who can joinFemale, 21 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. The SENTRY Study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer or an ovarian mass (and healthy control women), obtain platelet RNA samples from whole blood, and perform validation analyses to test our hypothesis.

This description comes directly from the study's public registry record.

Talk to the study team

Syrenna Lisonbee  ·  801-585-0161  ·  Syrenna.Lisonbee@hci.utah.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Huntsman Cancer InstituteSalt Lake City, Utah, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06665945